Daniel Lyons is a Research Analyst at Janus Henderson Investors, focusing on the biotechnology industry. Dr. Lyons started consulting for Janus in 1997 and joined the health care team full time in 2000.
Dr. Lyons received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a Ph.D. from Stanford University’s program in immunology and conducted postdoctoral research with a Nobel laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 18 years of financial industry experience.